Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role?
dc.contributor.author | Gönczi, Lóránt | |
dc.contributor.author | Végh, Zsuzsanna | |
dc.contributor.author | Golovics, Petra Anna | |
dc.contributor.author | Rutka, Mariann | |
dc.contributor.author | Gecse, Krisztina B. | |
dc.contributor.author | Bor, Renáta | |
dc.contributor.author | Farkas, Klaudia | |
dc.contributor.author | Szamosi, Tamás | |
dc.contributor.author | Bene, László | |
dc.contributor.author | Gasztonyi, Beáta | |
dc.contributor.author | Kristóf, Tünde | |
dc.contributor.author | Lakatos, László | |
dc.contributor.author | Miheller, Pál | |
dc.contributor.author | Palatka, Károly | |
dc.contributor.author | Papp, Mária | |
dc.contributor.author | Patai, Árpád | |
dc.contributor.author | Salamon, Ágnes | |
dc.contributor.author | Tóth, Gábor Tamás | |
dc.contributor.author | Vincze, Áron | |
dc.contributor.author | Bíró, Edina | |
dc.contributor.author | Lovász, Barbara Dorottya | |
dc.contributor.author | Kürti, Zsuzsanna | |
dc.contributor.author | Szepes, Zoltán | |
dc.contributor.author | Molnár, Tamás | |
dc.contributor.author | Lakatos, Péter | |
dc.date.accessioned | 2016-11-06T11:51:21Z | |
dc.date.available | 2016-11-06T11:51:21Z | |
dc.date.issued | 2017 | |
dc.date.oa | 2018-01-22 | |
dc.date.pasync | 2023-05-19T23:07:49Z | |
dc.date.updated | 2018-04-20T00:30:23Z | |
dc.description.corrector | KA | |
dc.identifier.citation | Journal of Crohns & Colitis. -11 : 6 (2017), p. 697-705. -J. Crohns Colitis. - 1873-9946 | |
dc.identifier.doi | http://dx.doi.org/10.1093/ecco-jcc/jjw203 | |
dc.identifier.issn | 1873-9946 | |
dc.identifier.opac | http://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM066060 | |
dc.identifier.scopus | 85029301295 | |
dc.identifier.uri | http://hdl.handle.net/2437/231758 | |
dc.identifier.url | https://academic.oup.com/ecco-jcc/article/11/6/697/2513724 | |
dc.identifier.wos | 000402604300006 | |
dc.language | eng | |
dc.rights.access | open access pre-print és post-print | |
dc.rights.owner | Oxford University Press | |
dc.subject.mab | Orvostudományok | |
dc.subject.mab | Klinikai orvostudományok | |
dc.tender | OTKA 115345 | |
dc.title | Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role? | |
dc.type | folyóiratcikk | |
dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nem elérhető
- Név:
- file_up_s1-ln250474041948365407-1939656818Hwf1920131987IdV89771242925047404PDF_HI0001.pdf
- Méret:
- 2.28 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- pre-print